|
|
Post by sla55 on Oct 4, 2018 17:47:47 GMT -5
www.geekwire.com/2018/secretive-startup-receptor-life-sciences-raises-7-5m-therapies-based-plant-extracts/Secretive biotechnology company Receptor Life Sciences has raised a funding round totaling just over $7.5 million, according to a filing with the Securities and Exchange Commission. A representative of the Seattle-area company confirmed that amount in response to an inquiry from GeekWire but declined to name investors or share details of its work. However, in separate filings with the U.S. Patent and Trademark Office, the company revealed that it is developing inhalable “pharmaceutical preparations with plant extracts” that could treat a variety of symptoms. Receptor has been around since 2015, but the company has been operating in stealth mode. Its website contains only an image of trees and a contact form, and only one person lists the company as their place of employment on LinkedIn: Andrea Leone-Bay, a New York-based biopharmaceutical executive whose profile says she is the company’s chief scientific officer. But the company has revealed some details about its work as part of a prolonged appeal with the United States Patent and Trademark Office in its effort to trademark its name. That appeal was rejected on Sept. 29, according to USPTO records. In filings with the trademark office, Receptor disclosed that it is developing pharmaceuticals based on plant extracts. The company declined to disclose what plant it is basing these drugs on. However, the list of possible targets includes many ailments that cannabis is often prescribed to treat: “pain, central nervous systems, metabolic disorders, gastrointestinal disorders” and “for use in side effects from chemotherapy.” The company also said the drugs will be inhalable, and that it is developing “inhalers sold prefilled with pharmaceutical preparations.” The SEC filing lists Traci Carman as the president of Receptor. Three other people are listed as directors: patent attorney Gregory Wesner, former high-ranking Starbucks executive Arthur Rubinfeld, who now runs a consumer-focused brand consulting company, and a David Thomson. The company is represented by lawyers from Lane Powell, where Wesner is a partner, and Lane Powell’s Seattle headquarters is listed as the address for the company in the SEC filing. An address in Seattle’s Magnolia neighborhood is listed on Receptor’s business license.
|
|
|
|
Post by gamblerjag on Oct 4, 2018 18:11:57 GMT -5
www.geekwire.com/2018/secretive-startup-receptor-life-sciences-raises-7-5m-therapies-based-plant-extracts/Secretive biotechnology company Receptor Life Sciences has raised a funding round totaling just over $7.5 million, according to a filing with the Securities and Exchange Commission. A representative of the Seattle-area company confirmed that amount in response to an inquiry from GeekWire but declined to name investors or share details of its work. However, in separate filings with the U.S. Patent and Trademark Office, the company revealed that it is developing inhalable “pharmaceutical preparations with plant extracts” that could treat a variety of symptoms. Receptor has been around since 2015, but the company has been operating in stealth mode. Its website contains only an image of trees and a contact form, and only one person lists the company as their place of employment on LinkedIn: Andrea Leone-Bay, a New York-based biopharmaceutical executive whose profile says she is the company’s chief scientific officer. But the company has revealed some details about its work as part of a prolonged appeal with the United States Patent and Trademark Office in its effort to trademark its name. That appeal was rejected on Sept. 29, according to USPTO records. In filings with the trademark office, Receptor disclosed that it is developing pharmaceuticals based on plant extracts. The company declined to disclose what plant it is basing these drugs on. However, the list of possible targets includes many ailments that cannabis is often prescribed to treat: “pain, central nervous systems, metabolic disorders, gastrointestinal disorders” and “for use in side effects from chemotherapy.” The company also said the drugs will be inhalable, and that it is developing “inhalers sold prefilled with pharmaceutical preparations.” The SEC filing lists Traci Carman as the president of Receptor. Three other people are listed as directors: patent attorney Gregory Wesner, former high-ranking Starbucks executive Arthur Rubinfeld, who now runs a consumer-focused brand consulting company, and a David Thomson. The company is represented by lawyers from Lane Powell, where Wesner is a partner, and Lane Powell’s Seattle headquarters is listed as the address for the company in the SEC filing. An address in Seattle’s Magnolia neighborhood is listed on Receptor’s business license. . OK I now believe SLA is RLS😎 |
|
|
|
Post by tomtabb on Oct 4, 2018 18:24:39 GMT -5
|
|
|
|
Post by mango on Oct 4, 2018 18:56:18 GMT -5
www.geekwire.com/2018/secretive-startup-receptor-life-sciences-raises-7-5m-therapies-based-plant-extracts/Secretive biotechnology company Receptor Life Sciences has raised a funding round totaling just over $7.5 million, according to a filing with the Securities and Exchange Commission. A representative of the Seattle-area company confirmed that amount in response to an inquiry from GeekWire but declined to name investors or share details of its work. However, in separate filings with the U.S. Patent and Trademark Office, the company revealed that it is developing inhalable “pharmaceutical preparations with plant extracts” that could treat a variety of symptoms. Receptor has been around since 2015, but the company has been operating in stealth mode. Its website contains only an image of trees and a contact form, and only one person lists the company as their place of employment on LinkedIn: Andrea Leone-Bay, a New York-based biopharmaceutical executive whose profile says she is the company’s chief scientific officer. But the company has revealed some details about its work as part of a prolonged appeal with the United States Patent and Trademark Office in its effort to trademark its name. That appeal was rejected on Sept. 29, according to USPTO records. In filings with the trademark office, Receptor disclosed that it is developing pharmaceuticals based on plant extracts. The company declined to disclose what plant it is basing these drugs on. However, the list of possible targets includes many ailments that cannabis is often prescribed to treat: “pain, central nervous systems, metabolic disorders, gastrointestinal disorders” and “for use in side effects from chemotherapy.” The company also said the drugs will be inhalable, and that it is developing “inhalers sold prefilled with pharmaceutical preparations.” The SEC filing lists Traci Carman as the president of Receptor. Three other people are listed as directors: patent attorney Gregory Wesner, former high-ranking Starbucks executive Arthur Rubinfeld, who now runs a consumer-focused brand consulting company, and a David Thomson. The company is represented by lawyers from Lane Powell, where Wesner is a partner, and Lane Powell’s Seattle headquarters is listed as the address for the company in the SEC filing. An address in Seattle’s Magnolia neighborhood is listed on Receptor’s business license. I laughed out loud. Love it. |
|
|
|
Post by sayhey24 on Oct 4, 2018 18:56:25 GMT -5
Arthur Rubinfeld is the former Chief creative officer and President, Global Innovation of Starbucks. Rubinfeld was responsible for overseeing the global creative studio including the disciplines of innovative brand marketing ideation, concept store design creation and product research & development QA/ QC execution.
Rubinfeld founded AIRVISION in 2002, a brand positioning strategic growth advisory company, with clients such as Microsoft, Omaha Steaks, adidas, Oakley, Potbelly Sandwich Works, and Cricket Communications.
The one guy I know who was at both Microsoft and Starbucks besides Rubinfeld was Rubinfeld's boss at Starbucks.
|
|
|
|
Post by mango on Oct 4, 2018 19:02:26 GMT -5
www.geekwire.com/2018/secretive-startup-receptor-life-sciences-raises-7-5m-therapies-based-plant-extracts/Secretive biotechnology company Receptor Life Sciences has raised a funding round totaling just over $7.5 million, according to a filing with the Securities and Exchange Commission. A representative of the Seattle-area company confirmed that amount in response to an inquiry from GeekWire but declined to name investors or share details of its work. However, in separate filings with the U.S. Patent and Trademark Office, the company revealed that it is developing inhalable “pharmaceutical preparations with plant extracts” that could treat a variety of symptoms. Receptor has been around since 2015, but the company has been operating in stealth mode. Its website contains only an image of trees and a contact form, and only one person lists the company as their place of employment on LinkedIn: Andrea Leone-Bay, a New York-based biopharmaceutical executive whose profile says she is the company’s chief scientific officer. But the company has revealed some details about its work as part of a prolonged appeal with the United States Patent and Trademark Office in its effort to trademark its name. That appeal was rejected on Sept. 29, according to USPTO records. In filings with the trademark office, Receptor disclosed that it is developing pharmaceuticals based on plant extracts. The company declined to disclose what plant it is basing these drugs on. However, the list of possible targets includes many ailments that cannabis is often prescribed to treat: “pain, central nervous systems, metabolic disorders, gastrointestinal disorders” and “for use in side effects from chemotherapy.” The company also said the drugs will be inhalable, and that it is developing “inhalers sold prefilled with pharmaceutical preparations.” The SEC filing lists Traci Carman as the president of Receptor. Three other people are listed as directors: patent attorney Gregory Wesner, former high-ranking Starbucks executive Arthur Rubinfeld, who now runs a consumer-focused brand consulting company, and a David Thomson. The company is represented by lawyers from Lane Powell, where Wesner is a partner, and Lane Powell’s Seattle headquarters is listed as the address for the company in the SEC filing. An address in Seattle’s Magnolia neighborhood is listed on Receptor’s business license. . OK I now believe SLA is RLS😎 Agree. |
|
|
|
Post by sla55 on Oct 4, 2018 19:09:50 GMT -5
cardinalweekly.com/receptor-life-sciences-7-57-million-fundraising-traci-carman-published-oct-3-form-d/Receptor Life Sciences $7.57 million Fundraising. Traci Carman Published Oct 3 Form D October 4, 2018 - By William Brooks Receptor Life Sciences Financing Receptor Life Sciences, Inc., Corporation just filed form D because of $7.57 million debt financing. The date of first sale was 2016-12-23. Receptor Life Sciences was able to finance itself with $7.57 million. That is 100.00 % of the round of financing. The total fundraising amount was $7.57 million. The financing form was filed on 2018-10-03. The reason for the financing was: unspecified. Receptor Life Sciences is based in Washington. The firm’s business is not disclosed. The form D was filed by Traci Carman President. The company was incorporated in 2015. The filler’s address is: C/O Lane Powell Pc, 1420 5Th Ave., Suite 4200, Seattle, Wa, Washington, 98101. Traci Carman is the related person in the form and it has address: C/O Lane Powell Pc, 1420 5Th Ave., Suite 4200, Seattle, Wa, Washington, 98101. Link to Receptor Life Sciences Filing: 000169376818000001. Analysis of Receptor Life Sciences Offering On average, startups in the not disclosed sector, sell 67.77 % of the total offering amount. Receptor Life Sciences sold 100.00 % of the offering. Could this mean that the trust in Receptor Life Sciences is high? The average fundraising size for companies in all industries in our database is $3.05 million. The total amount raised is 148.36 % bigger than the average for companies in the database. The minimum investment for this financing was set at $25000. If you know more about the reasons for the fundraising, please comment below. What is Form D? What It Is Used For Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer. Why Fundraising Reporting Is Good For Receptor Life Sciences Also The Form D signed by Traci Carman might help Receptor Life Sciences, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
|
|
|
|
Post by centralcoastinvestor on Oct 4, 2018 19:27:09 GMT -5
Just FYI, there is a David Thomson that is part of the management team at MannKind. He is a board member of RLS?
|
|
|
|
Post by mango on Oct 4, 2018 19:32:23 GMT -5
Just FYI, there is a David Thomson that is part of the management team at MannKind. He is a board member of RLS? MannKind's is David ThomPson nevermind you're right hmm looks like he is! |
|
|
|
Post by mango on Oct 4, 2018 19:34:02 GMT -5
|
|
|
|
Post by awesomo on Oct 4, 2018 19:54:44 GMT -5
It's probably this David Thomson (Precision BioSciences) |
|
|
|
Post by barnstormer on Oct 4, 2018 23:43:54 GMT -5
As a start up they need someone with a legal background. I would lean towards David B Thompson from MNKD's BOD.
David B. Thomson, PhD, JD, has been our General Counsel and Corporate Secretary since January 2002. Prior to joining us, he practiced corporate/commercial and securities law at the Toronto law firm of Davies Ward Phillips & Vineberg LLP. Earlier in his career, Dr. Thomson was a post-doctoral fellow at the Rockefeller University in New York. Dr. Thomson obtained his bachelor’s degree, master’s degree and Ph.D. degree from Queens University and obtained his J.D. degree from the University of Toronto.
|
|
|
|
Post by lakers on Oct 5, 2018 3:32:13 GMT -5
One stealth compound could be: Nabiximols (USAN,[1] trade name Sativex) is a specific extract of Cannabis that was approved as a botanical drug in the United Kingdom in 2010 as a mouth spray to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis; it was developed by the UK company GW Pharmaceuticals.[2][3] The drug is a pharmaceutical product standardised in composition, formulation, and dose. Its principal active cannabinoid components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD. In May 2003 GW Pharmaceuticals and Bayer entered into an exclusive marketing agreement for GW's cannabis-based medicinal extract product, to be marketed under the brand name Sativex. "Bayer has obtained exclusive rights to market Sativex in the UK. In addition, Bayer has the option for a limited period to negotiate the marketing rights in other countries in European Union and selected other countries around the world." In April 2011, GW licensed to Novartis the rights to commercialise nabiximols in Asia (excluding China and Japan), Africa and the Middle East (excluding Israel).[4] In June 2010, the Medicines and Healthcare products Regulatory Agency of the United Kingdom licensed nabiximols as a prescription-only medicine for the treatment of spasticity due to multiple sclerosis. This regulatory authorization represents the world's first full regulatory approval for the medicine. The spray is being marketed in the UK by Bayer Schering Pharma. Many people with MS cannot receive nabiximols due to local National Health Service (NHS) resistance to its funding;[5][6] but, in August 2014, the NHS in Wales agreed to fund Sativex for people with multiple sclerosis.[7] Nabiximols was also approved in Spain for MS spasticity in the second half of 2010 and was launched in that country in March 2011. It was approved in the Czech Republic in April 2011, in Germany in May 2011, in Denmark in June 2011 and in Sweden in January 2012 to people with MS who have not responded adequately to other medication for spasticity.[8] It has also been recommended for approval in Italy and Austria with formal approvals expected in these countries during 2011. In Spain and other European markets (excluding the UK), nabiximols will be marketed by Almirall. In Canada, nabiximols has been approved by Health Canada for the treatment of MS spasticity. It has also received a licence with conditions (NOC/c) for two additional uses: as adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis,[9] and also for pain due to cancer.[10][11] Nabiximols is available in a number of countries as an unlicensed medicine, which enables doctors to prescribe the product to people who they consider may benefit. The product has been exported from the UK to a total of 28 countries to date. In February 2007, GW and Otsuka Pharmaceutical announced an exclusive agreement for Otsuka to develop and market the drug in the United States. The first large scale US Phase IIb trial, Spray Trial, for people with cancer reported positive results in March 2010. GW and Otsuka have now commenced the Phase III development of nabiximols in cancer pain. In December 2012, Sativex was approved in Poland.[12] In 2013, France legalized the use of cannabinoids in medicine, Sativex is the first one to be sold under prescription.[13] Nevertheless, at least until June 2016, this drug was never actually sold in pharmacies there.[14] GW Pharmaceuticals were issued a unique license to cultivate cannabis for the manufacturing of Sativex in the UK, granting them the sole legal right to research in aerosolized cannabis derived therapeutics, which in April 2013 became commercially viable when the UK Government scheduled the Sativex formulation to part IV of the UK Drugs Act. en.m.wikipedia.org/wiki/Nabiximols61 Incredible Benefits of Marijuana (Backed by Science) www.herbonaut.com/benefits-of-marijuana/ |
|
|
|
Post by winner on Oct 5, 2018 5:46:11 GMT -5
Thanks for the info sla4235. I guess I'm going to the ATM machine again today. >25,000 shares <50,000. If I don't post on this forum in the next two days please contact the authorities. Chances are my Better Half found out and implemented corrective action. L.O.L. Best of luck to all MNKD Equity share holders...
|
|
|
|
Post by comnkd on Oct 10, 2018 15:01:16 GMT -5
Thanks for the info sla4235. I guess I'm going to the ATM machine again today. >25,000 shares <50,000. If I don't post on this forum in the next two days please contact the authorities. Chances are my Better Half found out and implemented corrective action. L.O.L. Best of luck to all MNKD Equity share holders... If your Better Half does find out just show them the RLS website. That should alleviate any concerns about your investing prowess...and also give them an idea where to bury you.  receptorlife.com |
|
